Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 1;28(8):802-810.
doi: 10.5551/jat.RV17053. Epub 2021 May 14.

Current Diagnosis and Management of Tangier Disease

Affiliations
Review

Current Diagnosis and Management of Tangier Disease

Masahiro Koseki et al. J Atheroscler Thromb. .

Abstract

Tangier disease is a genetic disorder characterized by an absence or extremely low level of high-density lipoprotein (HDL)-cholesterol (HDL-C). It is caused by a dysfunctional mutation of the ATP-binding cassette transporter A1 (ABCA1) gene, the mandatory gene for generation of HDL particles from cellular cholesterol and phospholipids, and it appears in an autosomal recessive hereditary profile. To date, 35 cases have been reported in Japan and 109 cases outside Japan. With dysfunctional mutations in both alleles (homozygotes or compound heterozygotes), the HDL-C level is mostly less than 5 mg/dL and there is 10 mg/dL or less of apolipoprotein A-I (apoA-I), the major protein component of HDL. In patients with Tangier disease, major physical findings are orange-colored pharyngeal tonsils, hepatosplenomegaly, corneal opacity, lymphadenopathy, and peripheral neuropathy. Although patients tend to have decreased low-density lipoprotein (LDL)-cholesterol (LDL-C) levels, premature coronary artery disease is frequently observed. No specific curative treatment is currently available, so early identification of patients and preventing atherosclerosis development are crucial. Management of risk factors other than low HDL-C is also important, such as LDL-C levels, hypertension and smoking. Additionally, treatment for glucose intolerance might be required because impaired insulin secretion from pancreatic beta cells has occasionally been reported.

Keywords: ABCA1; Atherosclerosis; Cholesterol efflux; HDL; Orange tonsil; Reverse cholesterol transport; Tangier disease.

PubMed Disclaimer

Figures

Fig.1.Roles of ABCA1 in formation of HDL particles, reverse cholesterol transport and pathogenesis of Tangier disease
Fig.1.Roles of ABCA1 in formation of HDL particles, reverse cholesterol transport and pathogenesis of Tangier disease
Fig.2. Orange-colored tonsils observed in male patient with Tangier disease in his 50s
Fig.2. Orange-colored tonsils observed in male patient with Tangier disease in his 50s
Arrow heads indicate palatine tonsil (left panel) and lingual tonsil (right panel). Reproduced from reference [8].
Fig.3. Abdominal CT scan of splenomegaly in female patient with Tangier disease in her 40s
Fig.3. Abdominal CT scan of splenomegaly in female patient with Tangier disease in her 40s
The photo was kindly provided by one of the co-authors, Prof. Yasushi Ishigaki (Iwate Medical University).
Fig.4. Advanced systemic atherosclerotic lesions in male patient with Tangier disease in his 50s
Fig.4. Advanced systemic atherosclerotic lesions in male patient with Tangier disease in his 50s
Arrows indicate stenosis or occlusion of the artery. A: left coronary artery, B: right coronary artery, C: brachiocephalic artery, D: left iliac artery, E: right external iliac artery [8].
Fig.5. Differential diagnosis flow chart for hypo-HDL-cholesterolemia
Fig.5. Differential diagnosis flow chart for hypo-HDL-cholesterolemia

Similar articles

Cited by

References

    1. Assmann G, Eckardstein A, Brewer HB. Familial analphalipoproteinemia: Tangier disease. The Metabolic and Molecular Bases of Inherited Diseases (McGraw Hill), 2001; 8th ed. vol 2: 2937-2960
    1. Fredrickson DS, Altrocchi PH, Avioli LV, Goodman DS, Goodman HC. Tangier disease.Combined clinical staff conference at the National Institutes of Health. Ann Intern Med, 1961; 55: 1016-1031
    1. Hara H, Yokoyama S. Interaction of free apolipoproteins with macrophages. Formation of high-density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem, 1991; 266: 3080-3086 - PubMed
    1. Francis GA, Knopp RH, Oram JF. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier disease. J Clin Invest, 1995; 96: 78-87 - PMC - PubMed
    1. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Genest J Jr, Hayden MR . Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet, 1999; 22: 336-345 - PubMed